Oral Dexmedetomidine in Pediatric MRI

The objective of this preliminary study is to assess the utility of oral dexmedetomidine as the sole sedative agent in pediatric population undergoing MRI

Inclusion Criteria:Subjects ages 4 months to 6 yearsUndergoing a clinically indicated MRI with anesthesiaExclusion Criteria:Refusal to take oral dexmedetomidineInability to take dexmedetomidine at least 90 minutes prior to start of the MRIKnown allergy to dexmedetomidineMedical contraindication to administration of dexmedetomidineUnstable cardiac status including life threatening arrhythmias, abnormal cardiac anatomy, significant cardiac dysfunctionCurrent use of digoxinMoya Moya diseaseNew onset strokeAmerican Society of Anesthesiologists (ASA) physical status classification system > IIContraindications to administering sedationActive and uncontrolled gastroesophageal refluxActive and uncontrolled vomitingCurrent or recent history of apneaActive respiratory disease including pneumonia, bronchitis, respiratory syncytial virus infection, asthma exacerbationCraniofacial anomalyUnable to have MRI